ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2602

Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas

Gaetane Nocturne1,2, Bineta Ly3, Saida Boudaoud4, raphaèle seror5,6, Laurence Zitvogel7 and Xavier Mariette8,9, 1Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, 2INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, 3INSERM U1184, Paris Sud University, Kremlin Bicetre, France, 4INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, 5Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, 6INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, 7IGR - INSERM U1015, Villejuif, France, 8Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, 9INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-TNF therapy, Natural killer (NK) cells and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) is associated with an increased risk of lymphoma linked to activity of the disease. Immunosuppressive drugs have been suspected to induce an additional risk. Since, NK cells have been recently shown to participate to anti–lymphoma immunosurveillance, we aimed to assess if anti-TNF might impact their anti-lymphoma activity.

Methods:

NK cells have been assessed ex vivo in patients with RA treated with methotrexate (MTX) with (n=19) or without (n=20) anti-TNF. Phenotype has been studied by flow cytometry and function (degranulation and IFNg production) has been assessed after NKp30-cross linking. Then, we have studied the consequences of in vitro exposure of NK to anti-TNF, to TNF-R inhibitors or to controls during 6 days: phenotype has been studied and then cytotoxicity against 2 B non-Hodgkin lymphoma cell lines [Farage (EBV+) and SU-DHL4 (EBV-)] was assessed.

Results are shown as median [interquartile range (IGR)]. The Mann Whitney test was used to compare independent samples.

Results:

Firstly, in patients, we found that the proportion of activated NK cells, assessed by the expression of CD69, was significantly decreased in patients treated with anti-TNF + MTX compared to patients treated with MTX alone (8.9% [2.9 – 40.7] vs 48.4% [27.4 – 58.3], p=0.005). Moreover, we found that NK cells exhibited an impaired function in patients treated with anti-TNF compared to patients treated with MTX alone as assessed by the percentage of degranulation (20.9% [18.5 – 32.9] vs 31.3% [21.5 – 49.1], p=0.04) and the loss of capacity of IFN-γ secretion ((17.4% [8.9 – 25.9] vs to 29.7% [22.5 – 43.1], p=0.007). Secondly, we have confirmed that in vitro exposure to anti-TNF negatively impact NK cells activation and function leading to an impaired anti-lymphoma activity (figure 1A). In all these experiments, no difference was observed between etanercept and monoclonal anti-TNF. Last, we have demonstrated that negative impact of anti-TNF on NK cells may be the consequence of inhibition of TNF-R1 signaling (figure 1B).

Conclusion:

Even if meta-analysis of randomized controlled trials and of registries have not demonstrated to date an increased risk of lymphoma with anti-TNF, cautious must be pursued concerning this possible side effect in patients with long-term exposure. Moreover, negative impact of anti-TNF on NK cells may participate to infectious adverse events.

Description: C:\Users\3206627\Desktop\figure.jpg

 


Disclosure: G. Nocturne, None; B. Ly, None; S. Boudaoud, None; R. seror, None; L. Zitvogel, None; X. Mariette, None.

To cite this abstract in AMA style:

Nocturne G, Ly B, Boudaoud S, seror R, Zitvogel L, Mariette X. Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/anti-tnf-therapy-is-associated-with-an-impaired-function-of-nk-cells-and-a-defective-immunosurveillance-against-b-cell-lymphomas/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-tnf-therapy-is-associated-with-an-impaired-function-of-nk-cells-and-a-defective-immunosurveillance-against-b-cell-lymphomas/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology